{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T13:49:53Z","timestamp":1788616193304,"version":"build-2803163510"},"reference-count":43,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2020,11,2]],"date-time":"2020-11-02T00:00:00Z","timestamp":1604275200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccines"],"abstract":"<jats:p>Background. Influenza prophylaxis with the use of quadrivalent vaccines (QIV) is increasingly being introduced into healthcare practice. Methods. In total, 32 healthy adults and 6 patients with common variable immunodeficiency (CVID) received adjuvant QIV during 2018\u20132019 influenza season. Depending on initial antibody titers, healthy volunteers were divided into seronegative (\u22641:20) and seropositive (\u22651:40). To evaluate immunogenicity hemagglutination inhibition assay was used. Results. All participants completed the study without developing serious post-vaccination reactions. Analysis of antibody titer 3 weeks after immunization in healthy participants showed that seroprotection, seroconversion levels, GMR and GMT for strains A\/H1N1, A\/H3N2 and B\/Colorado, B\/Phuket among initially seronegative and seropositive participants meet the criterion of CHMP effectiveness. CVID patients showed increase in post-vaccination antibody titer without reaching conditionally protective antibody levels. Conclusion. Adjuvant QIV promotes formation of specific immunity to vaccine strains, regardless of antibodies\u2019 presence or absence before. In CVID patients search of new regimens should be continued.<\/jats:p>","DOI":"10.3390\/vaccines8040640","type":"journal-article","created":{"date-parts":[[2020,11,2]],"date-time":"2020-11-02T09:04:46Z","timestamp":1604307886000},"page":"640","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Immunogenicity and Safety of the Quadrivalent Adjuvant Subunit Influenza Vaccine in Seropositive and Seronegative Healthy People and Patients with Common Variable Immunodeficiency"],"prefix":"10.3390","volume":"8","author":[{"given":"Mikhail P.","family":"Kostinov","sequence":"first","affiliation":[{"name":"Federal State Budgetary Scientific Institution, I.I. Mechnikov Research Institute of Vaccines and Sera, Malyi Kazenniy pereulok, 5a, 105064 Moscow, Russia"},{"name":"Federal State Autonomous Educational Institution of Higher Education, I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University), Trubetskaya Str., 8\/2, 119991 Moscow, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena A.","family":"Latysheva","sequence":"additional","affiliation":[{"name":"National Research Center\u2014Institute of Immunology Federal Medical-Biological Agency of Russia, Kashirskoe Shosse, 24, 115478 Moscow, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0584-2376","authenticated-orcid":false,"given":"Aristitsa M.","family":"Kostinova","sequence":"additional","affiliation":[{"name":"National Research Center\u2014Institute of Immunology Federal Medical-Biological Agency of Russia, Kashirskoe Shosse, 24, 115478 Moscow, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nelly K.","family":"Akhmatova","sequence":"additional","affiliation":[{"name":"Federal State Budgetary Scientific Institution, I.I. Mechnikov Research Institute of Vaccines and Sera, Malyi Kazenniy pereulok, 5a, 105064 Moscow, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatyana V.","family":"Latysheva","sequence":"additional","affiliation":[{"name":"National Research Center\u2014Institute of Immunology Federal Medical-Biological Agency of Russia, Kashirskoe Shosse, 24, 115478 Moscow, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna E.","family":"Vlasenko","sequence":"additional","affiliation":[{"name":"Novokuznetsk State Institute for Advanced Training of Physicians\u2014Branch Campus of the Russian Medical Academy of Continuous Professional Education, Prospect Stroiteley, 5, 654005 Novokuznetsk, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yulia A.","family":"Dagil","sequence":"additional","affiliation":[{"name":"National Research Center\u2014Institute of Immunology Federal Medical-Biological Agency of Russia, Kashirskoe Shosse, 24, 115478 Moscow, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ekaterina A.","family":"Khromova","sequence":"additional","affiliation":[{"name":"Federal State Budgetary Scientific Institution, I.I. Mechnikov Research Institute of Vaccines and Sera, Malyi Kazenniy pereulok, 5a, 105064 Moscow, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina B.","family":"Polichshuk","sequence":"additional","affiliation":[{"name":"Federal State Budgetary Scientific Institution, I.I. Mechnikov Research Institute of Vaccines and Sera, Malyi Kazenniy pereulok, 5a, 105064 Moscow, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2020,11,2]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/irv.12319","article-title":"Epidemiological and virological characteristics of influenza B: Results of the Global Influenza B Study","volume":"9","author":"Caini","year":"2015","journal-title":"Influ. Other Respir. Viruses"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"17","DOI":"10.22625\/2072-6732-2017-9-2-17-22","article-title":"The averted costs due to influenza vaccination with trivalent and quadrivalent vaccines","volume":"9","author":"Kharit","year":"2017","journal-title":"J. Infectol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"81","DOI":"10.4161\/hv.8.1.17623","article-title":"The rationale for quadrivalent influenza vaccines","volume":"8","author":"Ambrose","year":"2012","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Beran, J., Wertzova, V., Honegr, K., Kaliskova, E., Havl\u00ed\u010dkov\u00e1, M., Havl\u00edk, J., Ji\u0159incov\u00e1, H., Van Belle, P., Jain, V., and Innis, B.L. (2009). Challenge of conducting a placebo-controlled randomized efficacy study for influenza vaccine in a season with low attack rate and a mismatched vaccine B strain: A concrete example. BMC Infect. Dis., 9.","DOI":"10.1186\/1471-2334-9-2"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1016\/j.vaccine.2009.11.068","article-title":"Efficacy of live attenuated influenza vaccine in children against influenza B viruses by lineage and antigenic similarity","volume":"28","author":"Belshe","year":"2010","journal-title":"Vaccine"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"5572","DOI":"10.1016\/j.vaccine.2013.08.069","article-title":"Safety and immunogenicity of a quadrivalent inactivated influenza vaccine in adults","volume":"31","author":"Pepin","year":"2013","journal-title":"Vaccine"},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Kieninger, D., Sheldon, E., Lin, W.-Y., Yu, C.-J., Bayas, J.M., Gabor, J.J., Esen, M., Roure, J.L.F., Perez, S.N., and Sanchez, C.A. (2013). Immunogenicity, reactogenicity and safety of an inactivated quadrivalent influenza vaccine candidate versus inactivated trivalent influenza vaccine: A phase III, randomized trial in adults aged \u226518 years. BMC Infect. Dis., 13.","DOI":"10.1186\/1471-2334-13-343"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1016\/j.vaccine.2014.01.022","article-title":"Immunogenicity, reactogenicity, and safety of inactivated quadrivalent influenza vaccine candidate versus inactivated trivalent influenza vaccine in healthy adults aged \u226518 years: A phase III, randomized trial","volume":"32","author":"Tinoco","year":"2014","journal-title":"Vaccine"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1016\/j.vaccine.2012.11.074","article-title":"Safety and immunogenicity of a quadrivalent inactivated influenza vaccine compared to licensed trivalent inactivated influenza vaccines in adults","volume":"31","author":"Greenberg","year":"2013","journal-title":"Vaccine"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1016\/j.vaccine.2017.02.066","article-title":"Immunogenicity and safety of a quadrivalent inactivated influenza vaccine compared with two trivalent inactivated influenza vaccines containing alternate B strains in adults: A phase 3, randomized noninferiority study","volume":"35","author":"Treanor","year":"2017","journal-title":"Vaccine"},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Cowling, B.J., Perera, R.A.P.M., Valkenburg, S.A., Leung, N.H.L., Iuliano, A.D., Tam, Y.H., Wong, J.H.F., Fang, V.J., Li, A.P.Y., and So, H.C. (2019). Comparative Immunogenicity of Several Enhanced Influenza Vaccine Options for Older Adults: A Randomized, Controlled Trial. Clin. Infect. Dis.","DOI":"10.1093\/cid\/ciz1034"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.vaccine.2019.10.021","article-title":"Immunogenicity and safety of MF59-adjuvanted quadrivalent influenza vaccine versus standard and alternate B strain MF59-adjuvanted trivalent influenza vaccines in older adults","volume":"38","author":"Essink","year":"2019","journal-title":"Vaccine"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"3121","DOI":"10.1016\/j.vaccine.2020.02.055","article-title":"Clinical trial to assess immunogenicity of high-dose, adjuvanted, and recombinant influenza vaccines against cell-grown A(H3N2) viruses in adults 65 to 74 years, 2017\u20132018","volume":"38","author":"Belongia","year":"2020","journal-title":"Vaccine"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"92","DOI":"10.4161\/hv.26495","article-title":"A phase II study of an investigational tetravalent influenza vaccine formulation combining MF59\u00ae","volume":"10","author":"Herbinger","year":"2013","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_15","unstructured":"(2020, October 02). Instruction for Use of the Grippol\u00ae Quadrivalent. Available online: http:\/\/petrovax.ru\/upload\/iblock\/5b3\/Grippol_-Kvadrivalent-rastvor-dlya-vnutrimyshechnogo-i-podkozhnogo-vvedeniya."},{"key":"ref_16","unstructured":"Zverev, V.V., Semenov, B.F., and Khaitov, R.M. (2014). Vaccine and Vaccination: National Guideline, GEOTAR-Media. (In Russian)."},{"key":"ref_17","unstructured":"Kostinov, M.P., and Chuchalin, A.G. (2016). Manual on Clinical Immunology in Respiratory Medicine, Atmosfera Publishing Company LLC. [1st ed.]. (In Russian)."},{"key":"ref_18","unstructured":"Kostinov, M.P., and Tarasova, A.A. (2009). Vaccination of Pneumococcal Infection and Influenza in Autoimmune Diseases, MDV Group. Guide for Doctors."},{"key":"ref_19","first-page":"120","article-title":"A Study of the Clinical Safety of Pregnant Influenza Vaccination","volume":"4","author":"Cherdantsev","year":"2011","journal-title":"Med. Alm."},{"key":"ref_20","first-page":"44","article-title":"True and false reactions in pregnant women to introduction of influenza vaccine","volume":"10","author":"Kostinov","year":"2011","journal-title":"Gynecol. Obstet. Perinatol."},{"key":"ref_21","unstructured":"Zverev, V.V., Kostinov, M.P., and Cherdantsev, A.P. (2015). Vaccination against Influenza in Pregnancy, Remedium. (In Russian)."},{"key":"ref_22","first-page":"64","article-title":"The clinical and immunological safett of inactivated immunologic agjuvant influenza subunit vaccine for pregnant women","volume":"2","author":"Kostinov","year":"2016","journal-title":"Obstet. Ginecol."},{"key":"ref_23","first-page":"67","article-title":"The clinical and immunological safety of inactivated immunologic adjuvant influenza subunit vaccine for pregnant women","volume":"95","author":"Kostinov","year":"2016","journal-title":"Akusherstvo I Ginekologiya"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"43","DOI":"10.26442\/2079-5831_17.4.43-46","article-title":"Obstetric and perinatal outcomes among pregnant women after influenza vaccination and after transferred respiratory infection","volume":"17","author":"Kostinov","year":"2015","journal-title":"Gynecol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2693","DOI":"10.3389\/fimmu.2019.02693","article-title":"Polyoxidinium\u00ae activates cytotoxic lymphocyte responses through dendritic cell maturation: Clinical effects in breast cancer","volume":"10","author":"Alexia","year":"2019","journal-title":"Front. Immunol."},{"key":"ref_26","unstructured":"(2020, October 02). Vaccine Adjuvant \u00abPolyoxidonium\u00ae\u00bb Strengthens the Immune Response to a Low Dose of Influenza Antigens. Available online: https:\/\/www.elibrary.ru\/item.asp?id=39471103."},{"key":"ref_27","unstructured":"Chuchalina, A.G., and Yasnetsova, V.V. (2016). Federal Guideline on Medicine Use, OOO Vidoks. [17th ed.]. (In Russian)."},{"key":"ref_28","unstructured":"Kostinov, M.P. (2013). Vaccination of Children with Weak Health. Practical Manual for Doctors, Medicine for Everybody. [4th ed.]. (In Russian)."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.clim.2010.03.430","article-title":"Patients with humoral primary immunodeficiency do not develop protective anti-influenza antibody titers after vaccination with trivalent subunit influenza vaccine","volume":"136","author":"Holvast","year":"2010","journal-title":"Clin. Immunol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.1016\/j.vaccine.2016.03.091","article-title":"Cellular and humoral influenza-specific immune response upon vaccination in patients with common variable immunodeficiency and unclassified antibody deficiency","volume":"34","author":"Hanitsch","year":"2016","journal-title":"Vaccine"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.clim.2011.07.004","article-title":"Cell-mediated immune responses to inactivated trivalent influenza-vaccination are decreased in patients with common variable immunodeficiency","volume":"141","author":"Holvast","year":"2011","journal-title":"Clin. Immunol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1111\/j.1365-3083.2011.02561.x","article-title":"Pandemic Influenza Vaccination Elicits Influenza-Specific CD4+ Th1-cell Responses in Hypogammaglobulinaemic Patients: Four case reports","volume":"74","author":"Pedersen","year":"2011","journal-title":"Scand. J. Immunol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1093\/cid\/ciq104","article-title":"Humoral Response to the Influenza A H1N1\/09 Monovalent AS03-Adjuvanted Vaccine in Immunocompromised Patients","volume":"52","author":"Manuel","year":"2010","journal-title":"Clin. Infect. Dis."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"23","DOI":"10.36233\/0372-9311-2016-5-23-28","article-title":"The effect of influenza vaccines on blood dendritic cell subpopulations","volume":"5","author":"Khromova","year":"2016","journal-title":"J. Mikrobiol. Epidemiol. Immunobiol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"61","DOI":"10.36233\/0372-9311-2016-6-61-65","article-title":"Comparative Activity of Influenza Vaccines: Effect on Lymphocyte Subpopulation Structure","volume":"6","author":"Chromova","year":"2016","journal-title":"J. Mikrobiol. Epidemiol. Immunobiol."},{"key":"ref_36","first-page":"503","article-title":"Change of Lymphocyte Immunophenotype under the Influence of Immunoadjuvant and Nonadjuvant Influenza Vaccines","volume":"10","author":"Khromova","year":"2016","journal-title":"J. Microbiol. Epidemiol. Immunobiol."},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Saxena, S.K. (2018). Influenza\u2014Therapeutics and Challenges, IntechOpen. Chapter 5.","DOI":"10.5772\/intechopen.71939"},{"key":"ref_38","first-page":"505","article-title":"Influenza vaccines: Influence on TLRs expression","volume":"10","author":"Alexandrovna","year":"2016","journal-title":"Russ. Immunol. J."},{"key":"ref_39","first-page":"71","article-title":"Activation of Toll-like receptors with influenza vaccines (IN VITRO)","volume":"19","author":"Khromova","year":"2017","journal-title":"Med. Immunol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"24","DOI":"10.31631\/2073-3046-2017-16-2-24-30","article-title":"Comparative Assessment of Reactogenicity and Immunogenicity of Commercial Influenza Inactivated Vaccines: Polymer-Subunit Grippol plus, Subunit Influvac, Split Vaccine Waxigrip","volume":"16","author":"Kharit","year":"2017","journal-title":"Epidemiol. Vaccinal Prev."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1922","DOI":"10.1016\/j.jaci.2018.02.052","article-title":"Predictive markers for humoral influenza vaccine response in patients with common variable immunodeficiency","volume":"142","author":"Gardulf","year":"2018","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1046\/j.1365-2249.1998.00479.x","article-title":"Primary defect in CD8+ lymphocytes in the antibody deficiency diseases (common variable immunodeficiency): Abnormalities in intracellular production of interferon-gamma (INF-gamma) in CD28 (\u201ccytotoxic\u201d) and CD28- (\u201csuppressor\u201d) CD8+ subsets","volume":"111","author":"North","year":"1998","journal-title":"Clin. Exp. Immunol."},{"key":"ref_43","unstructured":"Setdikova, N. (2002). Immunomodulators in Complex Therapy of Immunocompromised Patients. [Ph.D. Thesis, NRC Institute of Immunology]. (In Russian)."}],"container-title":["Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-393X\/8\/4\/640\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T10:28:09Z","timestamp":1760178489000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-393X\/8\/4\/640"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,2]]},"references-count":43,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["vaccines8040640"],"URL":"https:\/\/doi.org\/10.3390\/vaccines8040640","relation":{},"ISSN":["2076-393X"],"issn-type":[{"value":"2076-393X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,2]]}}}